Welcome to the DZIF -
the German Center for Infection Research

Gastrointestinal Infections

Hepatitis

HIV

Infections of the Immunocompromised Host

Healthcare-Associated and Antibiotic-Resistant Bacterial Infections

Malaria and Neglected Tropical Diseases

Emerging Infections

Novel Antibiotics

Tuberculosis

Prof Ulrich Kubitscheck, Jan-Samuel Puls, Dominik Brajtenbach and Dr Fabian Grein (from left to right), all in white lab coats, photographed as a group in the lab.

Apr 29 2024

Lantibiotics: antibacterial substance with new mechanism of action discovered

A female health care worker in a red KCCR T-shirt stands in the centre of a circle of around 50 standing and sitting women, men and children in a square surrounded by a few houses.

Apr 26 2024

Zero maternal mortality in 2023 at Ghanaian cooperation hospital

The Presbyterian Hospital in Agogo, Ghana, recorded zero deaths among women during or after childbirth last year. This is a major medical success after 499 fatalities in 2020. The hospital management

From left to right: Prof. Luka Cicin-Sain, Head of the "Viral Immunology" Department at the HZI; Adhara Madhuri, PhD student at the HZI; Henrik Klimke, Chairman of the Günter Hansmeier Krebsstiftung.

Apr 15 2024

Doctoral project researches immunotherapy of CMV infections in children with leukaemia

Leukaemia is the most common cancer in children. Cancer treatment severely weakens the children's and they can easily develop opportunistic infections. One of the most common causes of

Schematic representation of the molecular blockade of the NTCP receptor by bulevirtide

Apr 8 2024

Mechanism of action of the hepatitis B and D virus cell entry inhibitor bulevirtide deciphered

Over 12 million people worldwide suffer from a chronic infection with the D virus. This most severe viral liver disease is associated with a high risk of dying from and liver

Mar 28 2024

Multidrug-resistant tuberculosis

is one of the challenges facing mankind in the 21st century. This includes antibiotic-resistant . Just in time for World Tuberculosis Day on 24 March 2024, the

All news

Tackling the world's deadliest infectious disease

24 March—World Tuberculosis Day

Tuberculosis researchers at the DZIF are combating this infectious disease, which is affecting millions of people worldwide, with new approaches in the treatment and diagnosis of infections and the monitoring of antibiotic resistance.

Cut-out from the cover of the 2022 annual report

pdf (3.36 MB)

DZIF Annual Report 2022

pdf (3.36 MB)

Video

Das zentrale Bioprobenregister im DZIF

Video

pdf (3.65 MB)

DZIF Annual Report 2021

pdf (3.65 MB)

Find Media Content

Hamburg - Lübeck - Borstel - Riems

Clinical Tuberculosis Centre

The Clinical Tuberculosis Centre provides the expertise and infrastructure for the optimisation, prevention, diagnosis and treatment of tuberculosis (TB) as well as for translating research results into clinical practice. The main objectives of the Clinical Tuberculosis Centre include coordinating clinical research activities involving the DZIF TB cohort. This cohort includes [...]

Hannover - Braunschweig | Heidelberg | München | Tübingen

Transplant Cohort

Medical data and biological samples obtained from transplant patients are collected and managed across Germany with the help of the DZIF Transplant Cohort. The data and samples form the basis of scientific studies which investigate the connections between numerous factors influencing an organ’s susceptibility to infection and organ function. In [...]

Tübingen

New strategies for specific eradication of Staphylococcus aureus

In this project, the scientists develop genetically engineered phage lysins and specific bacteriocins for the elimination of hospital germs such as Staphylococcus aureus, they clarify mechanisms of potential resistance mechanisms, and they analyse whether broad-spectrum or specifically acting agents have a more effective and lasting effect on colonization by [...]

Hannover - Braunschweig

Preclinical development of Amidochelocardins

The challenge of antibiotic drug development today is the discovery and optimisation of novel bioactive compounds that do not show cross-resistances with clinically applied antibiotics, ideally due to a novel mode of action (MoA) which adresses unexploited microbial targets. In the case of chelocardin, this antibiotic substance was identified several [...]